Pediatric anesthesia and neurotoxicity: can findings be translated from animals to humans?

Nicola Disma1, Tom G Hansen

  • 1Department of Pediatric Anesthesia, Giannina Gaslini Institute, Genoa, Italy - nicoladisma@gaslini.org.

Insights

Concerns about anesthesia

Area of Science:

  • Anesthesiology
  • Neuroscience
  • Pediatric Medicine

Background:

  • Animal studies suggest anesthetics may cause neurodegeneration in young brains.
  • This raises concerns about potential long-term neurocognitive impairment in children.
  • Epidemiological studies and prospective trials investigate anesthesia's effects on children.

Purpose of the Study:

  • To assess the association between early anesthesia exposure and long-term neurocognitive outcomes in children.
  • To compare neurological outcomes in infants receiving general versus regional anesthesia.
  • To evaluate the impact of a single, short exposure to anesthesia on infant neurodevelopment.

Main Methods:

  • Analysis of interim results from the GAS (General Anesthesia vs. Regional Anesthesia in Early Life) study.
  • Comparison of infants undergoing general anesthesia versus regional anesthesia for hernia repair.
  • Neurological outcome assessment at 2 years of age.

Main Results:

  • Interim findings from the GAS study indicate that a single, one-hour exposure to anesthesia does not negatively affect neurological outcomes at 2 years of age.
  • Animal study findings on anesthetic neurotoxicity are difficult to extrapolate to human pediatric populations.
  • Human studies are crucial for determining the actual risks of anesthesia in young patients.

Conclusions:

  • Current evidence suggests a single, short exposure to anesthesia in infancy may not cause significant long-term neurodevelopmental harm.
  • Animal research provides mechanistic insights but requires parallel human studies for clinical relevance.
  • Further research, including ongoing prospective trials, is needed to fully understand anesthesia's long-term effects on pediatric neurocognition.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
124
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
955
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
902
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
317